“This strategy, first reported by Patrice Yeh et al. in 1992 (8), … confer at least some of the stability and plasma longevity of albumin onto smaller fusion partners, such as … hirudin (9), interleukin 2 (10), brain natriuretic peptide (11), and interferon α-2b, the … phase 3 clinical trials (12).”